Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin ®) For The Treatment Of Three Types Of Cancer
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab)
Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer
THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin® (trastuzumab). ABP 980 has been recommended for approval for the treatment of the same three types of cancer as Herceptin is approved for in the European Union (EU), including HER2-pos...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Allergy | Breast Cancer | Cancer | Cancer & Oncology | European Medicines Agency (EMA) | HER2 | Herceptin | Marketing | Pharmaceuticals